<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275533</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-02167</org_study_id>
    <secondary_id>NCI-2014-02167</secondary_id>
    <secondary_id>CIRB 15-0185</secondary_id>
    <secondary_id>CVCIRB 15-0185</secondary_id>
    <secondary_id>9706</secondary_id>
    <secondary_id>9706</secondary_id>
    <secondary_id>N01CM00071</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <secondary_id>UM1CA186644</secondary_id>
    <secondary_id>UM1CA186686</secondary_id>
    <secondary_id>UM1CA186689</secondary_id>
    <secondary_id>UM1CA186691</secondary_id>
    <secondary_id>UM1CA186712</secondary_id>
    <secondary_id>UM1CA186717</secondary_id>
    <secondary_id>ZIABC011078</secondary_id>
    <nct_id>NCT02275533</nct_id>
  </id_info>
  <brief_title>Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy</brief_title>
  <official_title>Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well nivolumab works in eliminating any remaining cancer&#xD;
      cells and preventing cancer from returning in patients with acute myeloid leukemia that had a&#xD;
      decrease in or disappearance of signs and symptoms of cancer after receiving chemotherapy.&#xD;
      Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune&#xD;
      system attack the cancer, and may interfere with the ability of tumor cells to grow and&#xD;
      spread.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate and compare the progression free survival rate after randomization in the two&#xD;
      treatment arms (nivolumab versus [vs.] observation).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine and compare the overall survival rates in the two arms. II. To determine and&#xD;
      compare the incidence of non-relapse mortality in the two arms.&#xD;
&#xD;
      III. To evaluate the toxicities of nivolumab as maintenance.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To analyze programmed cell death (PD)-ligand (L)1 expression on acute myeloid leukemia&#xD;
      (AML) cells from peripheral blood and/or bone marrow samples at diagnosis if available and at&#xD;
      the time of study enrollment.&#xD;
&#xD;
      II. To monitor AML minimal residual disease (MRD) by Wilms tumor 1 (WT1) polymerase chain&#xD;
      reaction (PCR) at enrollment and at subsequent defined time points in the nivolumab-treated&#xD;
      and control groups.&#xD;
&#xD;
      III. To perform an exploratory analysis on the frequencies, absolute numbers and subsets of T&#xD;
      cells (including regulatory T cells) in the nivolumab-treated and control groups with an&#xD;
      emphasis on activation markers.&#xD;
&#xD;
      IV. To perform deep sequencing of T cell receptor (TCR)-alpha and TCR-beta chains on&#xD;
      polyclonal T cells at baseline and at subsequent time points in the nivolumab and control&#xD;
      groups.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive nivolumab intravenously (IV) over 60 minutes once every 2 weeks.&#xD;
      Treatment repeats every 2 weeks for 46 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients undergo standard of care clinical observation for up to 2 years. Upon&#xD;
      disease relapse, patients may cross-over to Arm I.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically for 2 years, every&#xD;
      6 months for 1 year, and then yearly thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 27, 2015</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Time from randomization to disease relapse or death from any cause, assessed up to 2 years post-treatment</time_frame>
    <description>Kaplan-Meier plots will be used to estimate PFS in each arm and a stratified log rank test will be performed to compare the two groups. In addition, Cox proportional hazards models will be fit to provide estimates of the hazard ratio (HR) and associated 95% confidence interval (CIs), both unadjusted and adjusted for baseline covariates. Descriptive, subset analysis of PFS will be performed for minimal residual disease (MRD) positive patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Time from randomization to the date of death from any cause, assessed up to 2 years post-treatment</time_frame>
    <description>For overall survival, Kaplan-Meier plots will be generated for each treatment arm and the curves will be compared using a log rank test. Kaplan-Meier estimates with 95% CI will be summarized every 6 months using Greenwood's formula for the standard error of the Kaplan-Meier estimate. In addition to the Kaplan-Meier estimates, Cox proportional hazards models will be fit to estimate HRs and to assess and adjust for the effects of covariates. Descriptive, subset analysis of OS will be performed for MRD negative patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>Duration between the date of randomization and the date of patient death due to reasons other than relapse, assessed up to 2 years post-treatment</time_frame>
    <description>NRM will be analyzed using competing risks models with deaths due to relapse as a competing risk. Cumulative incidence curves will be generated and treatment effects summarized using the sub-distribution hazard ratio with and without adjustment for covariates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects of nivolumab</measure>
    <time_frame>Up to 100 days post-treatment</time_frame>
    <description>Will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Summary tables for adverse events (AEs) will include only AEs that started or worsened after randomization. The incidence of treatment-related adverse events (new or worsening from baseline after randomization) will be summarized by system organ class and/ or preferred term, severity (based on CTCAE grades), type of adverse event, and relation to study treatment by treatment group. Toxicity rates will be compared between the two treatment arms via chi-squares or Fisher's exact tests.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I (nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nivolumab IV over 60 minutes once every 2 weeks. Treatment repeats every 2 weeks for 46 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (observation)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo standard of care clinical observation for up to 2 years. Upon disease relapse, patients may cross-over to Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Observation</intervention_name>
    <description>Undergo standard of care clinical observation</description>
    <arm_group_label>Arm II (observation)</arm_group_label>
    <other_name>observation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (nivolumab)</arm_group_label>
    <arm_group_label>Arm II (observation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (nivolumab)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>CMAB819</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>Nivolumab Biosimilar CMAB819</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AML patients in first complete remission (CR) (CR1) or first complete remission with&#xD;
             incomplete blood count recovery (CRi) after induction and consolidation chemotherapy;&#xD;
             except young (&lt; 60 years) AML patients in European LeukemiaNet favorable group; (Since&#xD;
             young AML patients in the European LeukemiaNet favorable group have excellent 2 year&#xD;
             progression free survival [PFS] at around 64%, further maintenance therapy might ot&#xD;
             provide additional benefit; thus the current trial will exclude young favorable group&#xD;
             AML patients), patients could receive any cycle consolidation or no consolidation per&#xD;
             the discretion by the treating physician&#xD;
&#xD;
          -  Within 60 days after bone marrow biopsy confirmed remission after the patients recover&#xD;
             from their last course of chemotherapy, the goal will be to consent the eligible&#xD;
             patient prior to the remission confirmation bone marrow biopsy at the end of the&#xD;
             planned chemotherapy); ideally, the research samples will be collected during the bone&#xD;
             marrow biopsy, and the patient will be enrolled to the study within 2 weeks of the&#xD;
             bone marrow biopsy; if there is delay to enroll the patient after the bone marrow&#xD;
             biopsy and research sample collection, it is ok not to repeat bone marrow biopsy&#xD;
             within 4 weeks, after the last bone marrow biopsy, if there is no sign of disease&#xD;
             relapse; a repeat bone marrow biopsy should be done if the delay of enrollment is more&#xD;
             than 4 weeks after the last bone marrow biopsy; patients with confirmed remission&#xD;
             within 60 days after the last bone marrow biopsy, without research samples collection,&#xD;
             should have a repeat bone marrow biopsy conducted within two weeks prior to enrolling&#xD;
             on the study&#xD;
&#xD;
          -  Patient is not a candidate for stem cell transplant due to advanced age or&#xD;
             co-morbidities; or the enrollee does not have donor available; or the enrollee&#xD;
             declines stem cell transplant due to personal belief; or stem cell transplant is not&#xD;
             standard of care based on the risk category of disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status of 0 or 1&#xD;
             (Karnofsky &gt;= 70%)&#xD;
&#xD;
          -  Life expectancy of greater than 6 months&#xD;
&#xD;
          -  Leukocytes &gt;= 1,500/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,000/mcL&#xD;
&#xD;
          -  Platelets &gt;= 50,000/mcL or recovery to the baseline count&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN) (except patients&#xD;
             with Gilbert syndrome, who can have total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Amylase and lipase =&lt; 1.5 x ULN without any symptoms of pancreatitis&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN OR creatinine clearance (CrCl) &gt;= 50 mL/min (if using&#xD;
             the Cockcroft-Gault formula)&#xD;
&#xD;
          -  The effects of nivolumab on the developing human fetus are unknown; for this reason,&#xD;
             women of child-bearing potential (WOCBP) and men must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control; abstinence) prior to study&#xD;
             entry and for the duration of study participation; WOCBP should use an adequate method&#xD;
             to avoid pregnancy for 23 weeks after the last dose of investigational drug nivolumab;&#xD;
             women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin&#xD;
             [HCG]) within 24 hours prior to the start of nivolumab; women must not be&#xD;
             breastfeeding; men who are sexually active with WOCBP must use any contraceptive&#xD;
             method with a failure rate of less than 1% per year; men receiving nivolumab and who&#xD;
             are sexually active with WOCBP will be instructed to adhere to contraception for a&#xD;
             period of 31 weeks after the last dose of investigational product; women who are not&#xD;
             of childbearing potential (i.e., who are postmenopausal or surgically sterile as well&#xD;
             as azoospermic men) do not require contraception&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) is defined as any female who has experienced&#xD;
             menarche and who has not undergone surgical sterilization (hysterectomy or bilateral&#xD;
             oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12&#xD;
             months of amenorrhea in a woman over 45 in the absence of other biological or&#xD;
             physiological causes; in addition, women under the age of 55 must have a documented&#xD;
             serum follicle stimulating hormone (FSH) level less than 40 mIU/mL&#xD;
&#xD;
          -  WOCBP receiving nivolumab will be instructed to adhere to contraception for a period&#xD;
             of 23 weeks after the last dose of investigational product; men receiving nivolumab&#xD;
             and who are sexually active with WOCBP will be instructed to adhere to contraception&#xD;
             for a period of 31 weeks after the last dose of investigational product; these&#xD;
             durations have been calculated using the upper limit of the half-life for nivolumab&#xD;
             (25 days) and are based on the protocol requirement that WOCBP use contraception for 5&#xD;
             half-lives plus 30 days and men who are sexually active with WOCBP use contraception&#xD;
             for 5 half-lives plus 90 days&#xD;
&#xD;
          -  Should a woman become pregnant or suspect she is pregnant while she or her partner is&#xD;
             participating in this study, she (or the participating partner) should inform the&#xD;
             treating physician immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) prior to entering the study or those who have not&#xD;
             recovered from adverse events (AEs) due to agents administered more than 4 weeks&#xD;
             earlier&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents&#xD;
&#xD;
          -  Patients should be excluded if they have had prior treatment with an anti-programmed&#xD;
             cell death protein 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), anti-PD-L2,&#xD;
             anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other&#xD;
             antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint&#xD;
             pathways&#xD;
&#xD;
          -  Patients with known central nervous system (CNS) involvement may be excluded because&#xD;
             of poor prognosis and concerns regarding progressive neurologic dysfunction that would&#xD;
             confound the evaluation of neurologic and other adverse events; however, if CNS&#xD;
             disease is cleared before the treatment with nivolumab, patients could be allowed if&#xD;
             no permanent CNS damage&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to any monoclonal antibody&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because nivolumab is an agent with the&#xD;
             potential for teratogenic or abortifacient effects; because there is an unknown but&#xD;
             potential risk for adverse events in nursing infants secondary to treatment of the&#xD;
             mother with nivolumab, breastfeeding should be discontinued if the mother is treated&#xD;
             with nivolumab&#xD;
&#xD;
          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)&#xD;
             or known acquired immunodeficiency syndrome (AIDS) might be enrolled if the viral load&#xD;
             by PCR is undetectable with/without active treatment and absolute lymphocyte count &gt;=&#xD;
             350/ul&#xD;
&#xD;
          -  Patients with a positive test for hepatitis B virus surface antigen (HBV sAg) or&#xD;
             hepatitis C virus ribonucleic acid (hepatitis C virus [HCV] antibody) indicating acute&#xD;
             or chronic infection might be enrolled if the viral load by PCR is undetectable&#xD;
             with/without active treatment&#xD;
&#xD;
          -  Patients with active autoimmune disease or history of autoimmune disease that might&#xD;
             recur should be excluded; these include but are not limited to patients with a history&#xD;
             of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating)&#xD;
             neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease&#xD;
             such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma,&#xD;
             inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients&#xD;
             with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or&#xD;
             phospholipid syndrome should be excluded because of the risk of recurrence or&#xD;
             exacerbation of disease; patients with vitiligo, endocrine deficiencies including&#xD;
             thyroiditis managed with replacement hormones including physiologic corticosteroids&#xD;
             are eligible; patients with rheumatoid arthritis and other arthropathies, Sj√∂gren's&#xD;
             syndrome and psoriasis controlled with topical medication and patients with positive&#xD;
             serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be&#xD;
             evaluated for the presence of target organ involvement and potential need for systemic&#xD;
             treatment but should otherwise be eligible&#xD;
&#xD;
          -  Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus,&#xD;
             residual hypothyroidism due to autoimmune condition only requiring hormone&#xD;
             replacement, psoriasis not requiring systemic treatment, or conditions not expected to&#xD;
             recur in the absence of an external trigger (precipitating event)&#xD;
&#xD;
          -  Patients should be excluded if they have a condition requiring systemic treatment with&#xD;
             either corticosteroids (&gt; 10 mg daily prednisone equivalents) or other&#xD;
             immunosuppressive medications within 14 days of study drug administration; inhaled or&#xD;
             topical steroids and adrenal replacement doses =&lt; 10 mg daily prednisone equivalents&#xD;
             are permitted in the absence of active autoimmune disease; patients are permitted to&#xD;
             use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids&#xD;
             (with minimal systemic absorption); physiologic replacement doses of systemic&#xD;
             corticosteroids are permitted, even if =&lt; 10 mg/day prednisone equivalents; a brief&#xD;
             course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for&#xD;
             treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction&#xD;
             caused by contact allergen) is permitted&#xD;
&#xD;
          -  Patients who have had evidence of active or acute diverticulitis, intra-abdominal&#xD;
             abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis should be&#xD;
             evaluated for the potential need for additional treatment before coming on study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongtao Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center EDDOP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center-North Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles County-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Center/Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center-International Plaza</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Comprehensive Cancer Center at Silver Cross</name>
      <address>
        <city>New Lenox</city>
        <state>Illinois</state>
        <zip>60451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine-Orland Park</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital-Westwood Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weisberg Cancer Treatment Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center-Einstein Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ben Taub General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 24, 2014</study_first_submitted>
  <study_first_submitted_qc>October 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

